UK Authorises Myqorzo and NICE Recommends It for Obstructive Hypertrophic Cardiomyopathy

Britain's Medicines and Healthcare products Regulatory Agency has approved Cytokinetics' drug Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy, while the National Institute for Health and Care Excellence recommended it for NHS reimbursement in England and Wales. The decision, supported by late-stage trial data showing improved exercise capacity, could benefit around 6,600 patients. This expands Myqorzo's footprint following its U.S. approval in December 2025.

UK regulatory approval

• ▪Britain's Medicines and Healthcare products Regulatory Agency approved Cytokinetics' drug Myqorzo for obstructive hypertrophic cardiomyopathy on July 30, 2026.
• ▪The United Kingdom approval of Myqorzo allows the drug to be used as a standalone treatment or alongside standard therapies.

NHS reimbursement recommendation

• ▪The National Institute for Health and Care Excellence recommended Myqorzo for National Health Service reimbursement in England and Wales on July 30, 2026.
• ▪The National Health Service reimbursement recommendation for Myqorzo is estimated to potentially reach about 6,600 eligible patients.
• ▪The National Institute for Health and Care Excellence recommendation covers adult patients with symptomatic obstructive hypertrophic cardiomyopathy classified as New York Heart Association class II or III.

Obstructive hypertrophic cardiomyopathy

• ▪Obstructive hypertrophic cardiomyopathy is a condition where abnormally thick heart muscle forms an obstruction that can reduce blood flow to the body.
• ▪Hypertrophic cardiomyopathy affects approximately 1 in 500 people in the United Kingdom, and the condition is inherited in roughly half of those cases.

Myqorzo clinical trial data

• ▪The Medicines and Healthcare products Regulatory Agency's approval of Myqorzo was supported by late-stage clinical trial data spanning 24 weeks.
• ▪Patients treated with Myqorzo for 24 weeks showed a statistically significant improvement in peak oxygen uptake compared to those receiving a placebo.

Cardiac myosin inhibitor class

• ▪Myqorzo, chemically known as aficamten, belongs to the cardiac myosin inhibitor class of drugs.
• ▪Bristol Myers Squibb's drug Camzyos is a cardiac myosin inhibitor approved for the treatment of obstructive hypertrophic cardiomyopathy.

US market expansion

• ▪The United States Food and Drug Administration approved Cytokinetics' drug Myqorzo in December 2025.
• ▪Cytokinetics initiated commercial sales of Myqorzo in the United States in January 2026.

1 source